Cancer statistics and trends in China: the potential of natural product application

Keywords

Cancer incidence / Mortality / Increasing trends / Natural products

References

[1] Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022[J]. CA Cancer J Clin, 2022, 72(5): 409-436.

[2] Chen SM, Cao Z, Prettner K, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050[J]. JAMA Oncol, 2023, 9(4): 465-472.

[3] Passaro A, Al-Bakir M, Hamilton EG, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment[J]. Cell, 2024, 187(7): 1617-1635.

[4] Weinstein IB. Cancer. Addiction to oncogenes: the achilles heal of cancer[J]. Science, 2002, 297 (5578): 63-64.

[5] Hnisz D, Weintraub AS, Day DS, et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods[J]. Science, 2016, 351(6280): 1454-1458.

[6] Liu JF, Lichtenberg T, Hoadley KA, et al. An integrated tcga pan-cancer clinical data resource to drive high-quality survival outcome analytics[J]. Cell, 2018, 173(2): 400-416.

[7] Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide[J]. Cancer, 2021, 127(16): 3029-3030.

[8] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.

[9] Han BF, Zheng RS, Zeng HM, et al. Cancer incidence and mortality in china, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.

[10] Zhang LL, Lu JJ. Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products[J]. Chin J Nat Med, 2024, 22(1): 1-3.

[11] Chen JX, Ding ZQ. Advances in natural product anti-coronavirus research (2002-2022)[J]. Chin Med, 2023, 18(1): 13.

[12] Luo ZW, Yin FC, Wang XB, et al. Progress in approved drugs from natural product resources[J]. Chin J Nat Med, 2024, 22(3): 195-211.

[13] Liu FY, Ding DN, Wang YR, et al. Icariin as a potential anticancer agent: a review of its biological effects on various cancers[J]. Front Pharmacol, 2023, 14: 1216363.

[14] Xiao ZJ, Hao YS, Liu BC, et al. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China[J]. Leuk Lymphoma, 2002, 43(9): 1763-1768.

[15] He XY, Fu JR, Lyu W, et al. Identification of bulbocodin D and C as novel stat3 inhibitors and their anticancer activities in lung cancer cells[J]. Chin J Nat Med, 2023, 21(11): 842-851.

[16] Peng Z, Wu WW, Yi P. The efficacy of ginsenoside Rg3 combined with first-line chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials[J]. Front Pharmacol, 2020, 11: 630825.

[17] Su MX, Xu YL, Jiang XM, et al. C-myc-mediated trib3/p62⁽⁺⁾ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2 [J]. Acta Pharm Sin B, 2022, 12(3): 1240-1253.

[18] Huang MY, Chen YC, Lyu WY, et al. Ginsenoside Rh 2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8(+) T cells via increasing intratumoral CXCL10 [J]. Pharmacol Res, 2023, 198: 106988.

[19] Shao T, Chen TZ, Chen YN, et al. Construction of paclitaxel-based antibody-drug conjugates with a pegylated linker to achieve superior therapeutic index[J]. Signal Transduct Target Ther, 2020, 5(1): 132.

[20] Liu MM, Martyn AP, Quinn RJ. Natural product-based proteolysis targeting chimeras (protacs)[J]. Nat Prod Rep, 2022, 39(12): 2292-2307.

[21] Garber K. The glue degraders[J]. Nat Biotechnol, 2024, 42(4): 546-550.

[22] Huang J, Zhu Y, Xiao H, et al. Formation of a traditional chinese medicine self-assembly nanostrategy and its application in cancer: a promising treatment[J]. Chin Med, 2023, 18(1): 66.

[23] Zhao J, Duan ZG, Ma XX, et al. Recent advances in systemic and local delivery of ginsenosides using nanoparticles and nanofibers[J]. Chin J Chem Eng, 2021, 30: 291-300.

Funding

Science and Technology Development Fund, Macau SAR(0015-2022-A1)

Science and Technology Development Fund, Macau SAR(005/2023/SKL)

University of Macau(MYRG-GRG2023-00160-ICMS-UMDF)

Internal Research Grant of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau(SKL-QRCM-IRG2023-011)